Alto Neuroscience, Inc. ((ANRO)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alto Neuroscience, Inc. is conducting a study titled ‘A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder.’ The study aims to assess the efficacy of ALTO-300, used alongside an antidepressant, compared to a placebo, focusing on patient characteristics. This research is significant as it could lead to more personalized treatment options for Major Depressive Disorder (MDD).
The intervention being tested is ALTO-300, an experimental drug administered as a capsule once daily in the evening. The study includes a placebo group for comparison, with both groups receiving treatment over a 42-day double-blind period, followed by an open-label extension for eligible participants.
The study design is interventional, with a randomized, parallel assignment model. It employs a quadruple masking approach, meaning that participants, care providers, investigators, and outcome assessors are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on May 26, 2023, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical study update could influence Alto Neuroscience’s stock performance positively if ALTO-300 demonstrates significant efficacy, potentially boosting investor confidence. In the competitive landscape of MDD treatment, successful results could position Alto Neuroscience as a leader in personalized mental health solutions.
The study is ongoing, with further details available on the ClinicalTrials portal.